Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, s...

Full description

Bibliographic Details
Main Authors: Alexander A. Azizi, Andreas V. Hadjinicolaou, Carla Goncalves, Adam Duckworth, Bristi Basu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
Combined hepatocellular-cholangiocarcinoma
cHCC-ICC
cHCC-CCA
biphenotypic
primary liver cancer
genomics
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.570958/full
id doaj-9128b3593a7f4db1894d56f813d03005
record_format Article
spelling doaj-9128b3593a7f4db1894d56f813d030052020-11-25T02:55:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-09-011010.3389/fonc.2020.570958570958Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular CholangiocarcinomaAlexander A. Azizi0Andreas V. Hadjinicolaou1Carla Goncalves2Adam Duckworth3Bristi Basu4Bristi Basu5Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomDepartment of Oncology, University of Cambridge, Cambridge, United KingdomCombined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.https://www.frontiersin.org/article/10.3389/fonc.2020.570958/fullCombined hepatocellular-cholangiocarcinomacHCC-ICCcHCC-CCAbiphenotypicprimary liver cancergenomics
collection DOAJ
language English
format Article
sources DOAJ
author Alexander A. Azizi
Andreas V. Hadjinicolaou
Carla Goncalves
Adam Duckworth
Bristi Basu
Bristi Basu
spellingShingle Alexander A. Azizi
Andreas V. Hadjinicolaou
Carla Goncalves
Adam Duckworth
Bristi Basu
Bristi Basu
Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
Frontiers in Oncology
Combined hepatocellular-cholangiocarcinoma
cHCC-ICC
cHCC-CCA
biphenotypic
primary liver cancer
genomics
author_facet Alexander A. Azizi
Andreas V. Hadjinicolaou
Carla Goncalves
Adam Duckworth
Bristi Basu
Bristi Basu
author_sort Alexander A. Azizi
title Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
title_short Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
title_full Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
title_fullStr Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
title_full_unstemmed Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
title_sort update on the genetics of and systemic therapy options for combined hepatocellular cholangiocarcinoma
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-09-01
description Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.
topic Combined hepatocellular-cholangiocarcinoma
cHCC-ICC
cHCC-CCA
biphenotypic
primary liver cancer
genomics
url https://www.frontiersin.org/article/10.3389/fonc.2020.570958/full
work_keys_str_mv AT alexanderaazizi updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
AT andreasvhadjinicolaou updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
AT carlagoncalves updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
AT adamduckworth updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
AT bristibasu updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
AT bristibasu updateonthegeneticsofandsystemictherapyoptionsforcombinedhepatocellularcholangiocarcinoma
_version_ 1724718391373070336

Similar Items